Opioids May Negatively Impact Hormone Health

Original post: Newswise - Substance Abuse Opioids May Negatively Impact Hormone Health

WASHINGTON—A new Scientific Statement released today by the Endocrine Society highlights research gaps associated with the negative effects of opioid use on the endocrine system.

The use and misuse of opioids are a growing global problem. Opioids are used to treat pain in people with cancer or other conditions (e.g., after an injury or surgery), however, they are highly addictive and people can develop opioid use disorder (OUD). The World Health Organization estimates 125,000 people died of opioid overdose in 2019.

The use and misuse of opioids has a negative effect on our hormones and can lead to reproductive, bone and adrenal health complications.

“Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement,” reviews data related to the use and misuse of opioids and the effects of these drugs on the endocrine system. The Statement discusses recent research on the clinical consequences of opioids, especially on the hypothalamic-pituitary system and bone health.

“We address the many research gaps associated with the effects and clinical consequences of opioids on the endocrine system within this Scientific Statement,” said lead Statement author Niki Karavitaki, M.Sc., Ph.D., F.R.C.P., of the University of Birmingham, Birmingham Health Partners, and the University Hospitals Birmingham National Health Service Foundation Trust in Birmingham, U.K. “We hope bringing attention to recent research in the space, including opioid use’s impact on gonadal, bone and adrenal conditions, will improve the endocrine health of people using or misusing opioids worldwide.”

The Statement reviews research related to the impact of opioids on gonadal and adrenal function, and bone health. The authors report male hypogonadism, a reproductive health condition that causes low testosterone, as a well-recognized side effect of opioids, and provide more clarity around the drug’s lesser-known effects on other parts of the hypothalamic-pituitary system and bone health. They discuss the link between opioids and the development of hyperprolactinemia and how more research is needed to understand their effect on secondary adrenal insufficiency. 

The Statement authors also assessed how opioids affect the secretion of certain hormones to better understand the connection between opioid use and endocrine disease. These hormones include growth hormone, arginine vasopressin (regulates the body’s water balance), and oxytocin (plays a crucial role in the childbirth process).

They also reviewed research into opioid’s actions on bone metabolism and their negative impact on bone mineral density and risk of fracture.

“Clinicians need to be aware of these endocrine health consequences and monitor patients who are using opioids more closely for signs and symptoms of them,” Karavitaki said.

Other statement authors are Jeffrey Bettinger of Saratoga Hospital Medical Group in Saratoga Springs, N.Y.; Nienke Biermasz of Leiden University Medical Center in Leiden, The Netherlands; Mirjam Christ-Crain of the University Hospital Basel and the University of Basel in Basel, Switzerland; Monica Gadelha of the Universidade Federal do Rio de Janeiro in Rio de Janeiro, Brazil; Warrick Inder of Princess Alexandra Hospital, Brisbane, and the University of Queensland, Brisbane, in Queensland, Australia; Elena Tsourdi of Technische Universität Dresden in Dresden, Germany; Sarah Wakeman of Massachusetts General Hospital, Mass General Brigham and Harvard Medical School in Boston, Mass.; and Maria Zatelli of the University of Ferrara in Ferrara, Italy.

The statement, “Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement,” was published online in the Society’s journal, Endocrine Reviews.

The Endocrine Society develops Scientific Statements to explore the scientific basis of hormone-related conditions and disease, discuss how this knowledge can be applied in practice, and identify areas that require additional research. Topics are selected on the basis of their emerging scientific impact. Scientific Statements are developed by a Task Force of experts appointed by the Endocrine Society, with internal review by the relevant Society committees and expert external reviewers prior to a comment period open to all members of the Society.

# # #

Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.

Voters Fret High Medical Bills Are Being Ignored by Presidential Rivals

Tom Zawierucha, 58, a building services worker in New Jersey, wishes candidates would talk more about protecting older Americans from big medical bills.

Teresa Morton, 43, a freight dispatcher in Memphis, Tennessee, with two teenagers, wants to hear more about how elected officials would help working Americans saddled with unaffordable deductibles.

Yessica Gray, 28, a customer support representative in Wisconsin, craves relief from high drug prices and medical bills that have driven her and her husband deep into debt. “How much are we going to pay?” she said. “It’s just something that’s always on my mind.”

Health care hasn’t figured prominently in this increasingly acrimonious presidential campaign. And the economy has generally topped the list of voters’ concerns.

But Americans remain intensely worried about paying for medical care, national surveys show.

Two in 3 U.S. adults in a recent nationwide poll by West Health and Gallup said they’re concerned a major health event would land them in debt. A similar share said health care isn’t getting enough attention in the campaign.

To better understand voters’ health care concerns as the 2024 campaign nears an end, KFF Health News worked with research firm PerryUndem to convene a pair of focus groups last week with 16 people from across the country. PerryUndem is a nonpartisan firm based in Washington, D.C., that studies public views on health care and other issues.

A photo of several people on a Zoom video call.
Voters from across the country discuss their health care concerns ahead of the November elections in a focus group convened by research firm PerryUndem in collaboration with KFF Health News. Many in the group expressed dismay that the candidates haven’t talked more about the big medical bills patients face.(Noam N. Levey/KFF Health News)

The focus group participants represented a broad swath of the electorate, with some favoring Republican candidates, and others Democrats. But nearly all shared a common complaint: Neither presidential candidate has talked enough about how they’d help people struggling to pay for medical care.

“You don’t really hear anything much about health care costs,” said Bob Groegler, 46, who works in residential financing in eastern Pennsylvania. Groegler said he’s worried he may never be able to retire because he won’t have enough money to pay his medical bills.

Former President Donald Trump, the Republican nominee, hasn’t offered a detailed health care agenda, though he criticizes current laws and said he has “concepts of a plan” to improve the 2010 Affordable Care Act, often called Obamacare.

Vice President Kamala Harris, a Democrat, has laid out more detailed health care proposals, including building on legislation signed by President Joe Biden to lower patients’ bills.

In 2022, Biden signed the Inflation Reduction Act, which limits how much Medicare enrollees must pay out-of-pocket for prescription drugs, including a $35 monthly cap on insulin. The legislation also provides additional federal aid to help Americans buy health insurance through the Affordable Care Act, though this aid will expire unless Congress and the president renew it next year.

Harris has said she will expand the aid and push for new assistance to Medicare enrollees who need home care. She also has pledged to continue federal efforts to relieve medical debt, a nationwide problem that burdens about 100 million people.

But most of the focus group participants said they knew little about these proposals, complaining that hot-button issues like abortion have dominated the campaign.

Many also expressed deep skepticism that either Harris or Trump would do much to lighten the burden of medical bills.

“I believe they’re out of touch with our reality,” said Renata Bobakova, 46, a teacher and mother outside Cleveland. “We never know when we’ll get sick. We never know when we’ll fall down or sprain an ankle. And prices really can be astronomical. … I’m constantly worried about that.”

Bobakova, who is from Slovakia, said she went back to Europe to give birth to her daughter 10 years ago to avoid crippling medical debt she knew she’d incur in this country. Parents with private health coverage face on average more than $3,000 in medical bills related to a pregnancy and childbirth that aren’t covered by insurance.

Other focus group participants said they or people they knew had left the country to get cheaper prescription drugs. The U.S. has the highest medical prices in the world, research shows.

A photo of several people on a Zoom video call.
The focus group participants represented a broad swath of the electorate, with some favoring Republican candidates and others Democrats. But nearly all shared a complaint: Neither presidential candidate has talked enough about how they’d help people struggling to pay for medical care.(Noam N. Levey/KFF Health News)

Several focus group participants, such as Kevin Gaudette, 64, a retired semiconductor engineer in North Carolina, blamed large hospitals, drug companies, and insurers for blocking efforts to lower patients’ costs to protect their profits. “I think everybody has their finger in the pie,” Gaudette said.

Martha Chapman, 64, who is also retired and lives in Philadelphia, pointed to what she called “corporate greed.” “I just don’t think it’s going to change,” she said.

In the closing days of the campaign, that cynicism represents a particular problem for Harris, said PerryUndem co-founder Michael Perry, who led the two focus groups.

Harris has tried to distinguish herself as the candidate who is more serious about policy and more sympathetic to voters’ economic struggles, Perry said. And in recent weeks, she’s begun airing new ads highlighting health care issues.

But even focus group participants who said they lean Democratic seemed to blame both candidates for not addressing Americans’ health care concerns. “They’re not feeling listened to,” Perry said.

Many of the participants nevertheless continued to express hope that an issue as important as health care would someday get the attention of elected officials, regardless of political party.

“We’re all human beings here. We’re all people just trying to make it,” said Zawierucha, the building services worker in New Jersey. “If we get sick or have to go in and get something done, we should have that peace of mind that we can go in there and not have to worry about paying it off for the next 20 years.”

“Just give us some peace of mind,” he said.

This article was produced by KFF Health News, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — the independent source for health policy research, polling, and journalism. 

A California Official Helped Save a Mental Health Company’s Contract. It Flew Him to London.

The director of California’s mental health commission traveled to London this summer courtesy of a state vendor while he was helping to prevent a $360 million budget cut that would have defunded the company’s contract.

Emails and calendars reviewed by California Healthline show Toby Ewing, executive director of the Mental Health Services Oversight and Accountability Commission, made efforts to protect funding for Kooth, a London-based digital mental health company the state hired to develop a virtual tool to help tackle its youth mental health crisis. Ewing pressed key legislative staffers to maintain its contract, even as Democratic Gov. Gavin Newsom and lawmakers proposed cuts in the face of California’s $45 billion deficit.

When Ewing and three commissioners — Mara Madrigal-Weiss, the commission chair; Bill Brown; and Steve Carnevale — left for London in June, Ewing wasn’t sure whether he had saved Kooth’s funding. On the second day of their trip, staff informed him that lawmakers had restored the money.

A few days later, he emailed Kooth Chief Operating Officer Kate Newhouse suggestions he had shared with Assembly and Senate staff to improve Kooth’s youth teletherapy app. “We expect you to be involved in whatever we dream up,” Ewing wrote to Newhouse in another email.

It’s unclear why Kooth picked up a $15,000 tab for state officials to travel to London. It’s also unclear why Ewing pushed to protect its app from a spending cut. The commission is a 16-member independent body appointed by various elected officials to help ensure funds from a millionaires tax are used appropriately and effectively by counties for mental health services. Kooth’s contract is with the Department of Health Care Services, which is separate from the commission.

Kooth last year signed a four-year $271 million contract to create Soluna, a free mental health app for California users ages 13 to 25. The app, along with another, by the company Brightline, for younger users, launched in January to fill a need for young Californians and their families to access professional telehealth for free. It’s one component of Newsom’s $4.7 billion youth mental health plan.

Ewing, who reports to the commission, started in 2015 and earned $175,026 in 2023, according to The Sacramento Bee. He was placed on paid administrative leave in September pending an investigation. Commission chief counsel Sandra Gallardo said the commission does not comment on personnel matters. Ewing did not respond to requests for comment.

Three commission employees filed whistleblower complaints against Ewing in September with the California State Auditor. They spoke with California Healthline on the condition that their names not be used due to fears of workplace retaliation. They say Ewing’s conduct advancing a private company’s agenda as a public official crossed a line.

The agenda for Thursday’s commission meeting listed a personnel matter to be discussed in closed session. The whistleblowers said Ewing is the subject of the discussion.

Madrigal-Weiss said she couldn’t comment on Ewing’s actions. However, she said the commission supports virtual mental health resources for youth.

“These resources are less expensive and have proven valuable for youth, especially those who struggle to access services in typical brick-and-mortar spaces,” said Madrigal-Weiss, who is also executive director of student wellness and school culture for the San Diego County Office of Education.

Brown and Carnevale didn’t respond to requests for comment.

Kooth is committed to advancing youth access to behavioral health services, said Caroline Curran, of Metis Communications, a public relations firm representing Kooth.

“As a leader in youth behavioral health services with over 20 years of experience in the United Kingdom and the United States, we regularly convene sector-leading organizations to facilitate learning through sharing expertise and diverse perspectives on youth behavioral health,” Curran said.

As California Healthline reported in April, the Kooth and Brightline app rollouts have been slow, with few children using them. In May, Newsom proposed a $140 million budget cut. DHCS Director Michelle Baass said in a hearing that it was due to low use, but the state expects more users to come on board over time.

She told lawmakers on May 16 that roughly 20,000 of the state’s more than 12.6 million children and young adults had registered on the apps, and they had been used for only about 2,800 coaching sessions.

State Sen. Caroline Menjivar (D-Van Nuys) asked Baass at the hearing whether “there’s room to get out” of the contract altogether. Senators later voted unanimously to cut the entire platform budget to save the state $360 million.

Ewing texted a colleague on June 3: “Kooth is freaking out.  Is the cut coming from the Admin or the Leg.? Do we know if it’s a done deal?”

State lobbying records show Kooth has paid around $100,000 this year to the firm Capital Advocacy. At the same time, Ewing’s emails and calendars show that he pushed for Kooth’s funding to be retained. For instance, his June 4 calendar shows he was scheduled to meet with Laura Tully, an executive from Kooth USA, at a coffee shop near the Capitol.

The next day, a whistleblower said, Ewing met with key Senate staff members: Scott Ogus, deputy staff director of the Senate Budget and Fiscal Review Committee, and Marjorie Swartz, a consultant for Senate President Pro Tempore Mike McGuire. They said Ewing also discussed Kooth’s contract that week with Rosielyn Pulmano, a health policy consultant for Assembly Speaker Robert Rivas.

“Toby kept saying that ‘California has to have a digital strategy,’” recalled the whistleblower, who attended both meetings. “He kept pushing Marjorie and Scott, saying that he would give them ideas to make the platform better.”

Ewing emailed ideas to the legislative aides on June 10 and 12.

About two weeks later, he and the commissioners left for the seven-day trip to the U.K. According to documents filed with the state Fair Political Practices Commission, receipts, and emails reviewed by California Healthline, Kooth covered the costs of four-star hotels, meals, train tickets, and international flights.

Public disclosure forms show Kooth paid expenses for Ewing, Madrigal-Weiss, and Brown. The forms do not show the company paid for Carnevale’s travel.

Under California law, state officials generally must report travel payments to the FPPC, which Ewing and his fellow commissioners did.

Kooth postponed a mental health investment conference in London in June, emails and documents show, but then organized new events for the California commissioners to attend instead.

On May 23, Newhouse informed Carnevale and Ewing in an email that Kooth needed to postpone the planned June event. Carnevale, a venture capitalist, described the news as “disappointing for all,” especially “because we have already booked trips, including family members of Commissioners who were planning to turn this into a holiday.”

Acknowledging the disruption, Newhouse told Carnevale that she “would like to think creatively as to whether we could try to arrange a meeting where you can talk about the CYBHI,” referring to Newsom’s Children and Youth Behavioral Health Initiative.

“I know though from our conversation that we need to cover the ‘purpose’ of your trip and not sure what is possible or not,” she wrote.

Curran, the Kooth spokesperson, said the company “adapted by holding a knowledge exchange between representatives from international policy institutes, research foundations, and non-profit organizations.”

Madrigal-Weiss defended the trip, which she said included meetings with “members of the government, service providers, education, and finance” who shared ideas on how “to enhance funds for public mental health needs” through private and philanthropic partnerships.

One of the whistleblowers said many of the commissioners back in California were not aware of the trip until their colleagues were halfway across the world. Sami Gallegos, a spokesperson for the California Health and Human Services Agency, said the Department of Health Care Services did not participate in the travel.

Ewing was put on leave before Kooth’s rescheduled conference this month in London.

Although it’s not unusual for state officials to travel overseas — often on the dime of private entities — it doesn’t look good, said Sean McMorris, a government ethics expert with California Common Cause, a nonprofit government watchdog group.

“It looks like undue influence,” McMorris said. “I think a lot of people would view something like this as a way to curry favor. You can connect the dots.”

Kooth has similarly gifted travel to state officials in Pennsylvania, where it had a $3 million contract with 30 school districts. In each case, Kooth invited the officials to speak to highlight their work. Pennsylvania has informed Kooth it intends to terminate the contract.

Implantable Device May Prevent Death From Opioid Overdose

Original post: Newswise - Substance Abuse Implantable Device May Prevent Death From Opioid Overdose

BYLINE: Marta Wegorzewska

Newswise — The opioid epidemic claims more 70,000 lives each year in the U.S., and lifesaving interventions are urgently needed. Although naloxone, sold as an over-the-counter nasal spray or injectable, saves lives by quickly restoring normal breathing during an overdose, administrating the medication requires a knowledgeable bystander ­– limiting its lifesaving potential.

A team from Washington University School of Medicine in St. Louis and Northwestern University in Chicago has developed a device that may rescue people from overdose without bystander help. In animal studies, the researchers found that the implantable device detects an overdose, rapidly delivers naloxone to prevent death and can alert emergency first responders.

The findings are available Oct. 23 in Science Advances.

“Naloxone has saved many lives,” said Robert W. Gereau, PhD, the Dr. Seymour and Rose T. Brown Professor of Anesthesiology and director of the WashU Medicine Pain Center. “But during an overdose, people are often alone and unable to realize they are overdosing. If someone else is present, they need access to naloxone — also known as Narcan — and need to know how to use it within minutes. We identified an opportunity to save more lives by developing a device that quickly administers naloxone to at-risk individuals without human intervention.”

Prescription opioids – such as oxycodone – have helped people manage the physical and mental challenges of daily debilitating pain. But the addictive properties of painkillers can lead to their misuse and abuse, which are among the driving forces behind the opioid epidemic. In addition, cheap and easy-to-access synthetic drugs – fentanyl, for example – have flooded the illicit market. Such ultrapotent drugs have accelerated the rise in overdose deaths in the U.S. and were responsible for roughly 70% of such deaths in 2023.

The researchers worked with experts in engineering and material sciences led by John A. Rogers, PhD, a professor of materials science and engineering, biomedical engineering and neurological surgery at Northwestern University, to develop a device ­– the Naloximeter – that uses a drop in oxygen levels as a signal for a potential overdose. Overdosing on opioids leads to slow and shallow breathing. Minutes after the drugs begin to impact respiratory function, breathing stops. Implanted under the skin, the Naloximeter senses oxygen in the surrounding tissues, sending a warning notification to a mobile application if the levels drop below a threshold. If the user doesn’t abort the rescue process within 30 seconds, the device releases stored naloxone.

Implanted under the skin, the Naloximeter, developed by researchers at WashU Medicine and Northwestern University, senses dropping oxygen in the surrounding tissues and sends a warning notification to a mobile application. If the user doesn’t engage with the warning message within 30 seconds, the device releases stored naloxone and can send an alert to first responders.

The researchers implanted the device in the neck, chest or back of small and large animals. The device detected signs of overdose within a minute of dropping oxygen levels, and all animals fully recovered within five minutes of receiving naloxone from the devices.

Naloxone displaces harmful opioids from receptors on the surface of brain cells, altering the cells’ activity. But the drug doesn’t stick around; when the opioids reoccupy and reactivate the receptors, overdose symptoms can return. To provide additional support, the device relays an emergency alert to first responders.

“An additional benefit of calling first responders is that it helps people re-engage with health-care providers,” said Jose Moron-Concepcion, PhD, the Henry E. Mallinckrodt Professor of Anesthesiology at WashU Medicine and an author on the study. “We want to save people from dying from an overdose and also reduce harm from opioids by helping people access the resources and treatments to prevent future overdoses from occurring.”

The researchers were awarded a patent – with some help from the Office of Technology Management at WashU – to protect the intellectual property of the device.

“The Naloximeter is a proof-of-concept platform that isn’t limited to the opioid crisis,” said Joanna Ciatti, a graduate student in Rogers’ lab. “This technology has far-reaching implications for those threatened by other emergent medical conditions such as anaphylaxis or epilepsy. Our study lays important groundwork for future clinical translation. We hope others in the field can build off of these findings to help make autonomous rescue devices a reality.”

Crackdown on Homeless Encampments Raises Public Health Questions

As states turn to the health-care system to help address homelessness, experiments with housing and other social services aimed at getting people healthier and off the streets are running up against new, aggressive crackdowns — with some cities ratcheting up enforcement of existing anticamping laws and others passing new restrictions.

From Florida to California, elected officials and law enforcement agencies have launched widespread operations targeting homeless people following the U.S. Supreme Court’s ruling in June that makes it easier for states, cities and counties to fine and arrest those living outside — even if there is no shelter or housing available.

“These tactics cause chaos, not order. They are not a solution to homelessness, and in fact, they will make the problem worse,” said Ann Oliva, CEO of the National Alliance to End Homelessness.

The sweeps are a response to rising public frustration over the proliferation of homeless encampments and the public health hazards that often accompany them.

But a growing body of evidence indicates that housing services and health care can help get people off the streets while stabilizing their health. What to do about homelessness has become a rising political issue.

“Voters believe mental health and physical health care are important parts of the solution,” said Celinda Lake, a national Democratic pollster. “They feel if you just arrest people and move them around, you’re just going to make the situation worse. Voters want real solutions. That’s what we’ve heard from Minnesota to Tulsa, to Omaha, Nebraska, and even Great Falls, Montana.”

Politicians are responding to the visibility of homelessness by clearing encampments, but in doing so, they are thwarting efforts to stabilize people and make them healthier.

Those sweeps are breaking crucial connections to street medicine providers, housing navigators and case managers funded by Medicaid and through other state and national programs, including the federal Health Care for the Homeless program launched in 1987 to improve the health of those living outside.

As law enforcement operations expand, health-care providers on the ground say the efforts are making people sicker. Homeless people are skipping medical appointments, losing their medications, and having their IDs, birth certificates and other vital documents thrown away, slowing efforts to get them indoors.

Health and social service providers in cities across the West, where there has been a surge in people living outdoors, also report an uptick among homeless people in substance use, thoughts of suicide and other mental health issues such as anxiety and depression.

“There’s all this health-care money to try to stabilize people and get them to a place where they can get healthy, but if they’re constantly being forced to move, we can’t find them,” said Beth Rittenhouse-Dhesi, a longtime street medicine provider in San Francisco.

“People are losing their medications or getting them thrown away, and all of a sudden, conditions like diabetes, hypertension, HIV, asthma, opioid use … are becoming significantly worse,” because they are left untreated.


This article is not available for syndication due to republishing restrictions. If you have questions about the availability of this or other content for republication, please contact [email protected].


Can You Rely on Your Mammogram To Identify Heart Disease Risk?

Jackie Fortiér reported the audio story.

When people check in for their annual mammogram these days, some may face a surprising question: In addition to reviewing the mammogram for breast cancer, would the patient like the radiologist to examine the images for heart disease risk?

That’s what happened recently when a colleague visited Washington Radiology, a practice with more than a dozen locations in Washington, D.C., Maryland, and Virginia.

For $119, she was told, the practice would use artificial intelligence software to analyze her mammogram for calcification in the arteries of her breasts, which could indicate she’s at risk for cardiovascular disease.

Washington Radiology is one of a number of practices nationwide offering this type of screening. Here’s what to know about the screening and whether research supports it.

Although breast X-rays are typically used to detect and diagnose breast cancer, the pictures also indicate whether the arteries in the breast have calcifications, which show up as parallel white lines on the film. Calcifications, which are considered “incidental” findings unrelated to breast cancer, may be associated with someone’s heart disease risk. They’ve been visible on images for decades, and some radiologists have routinely noted them in their reports. But the information hasn’t typically been passed on to patients.

Now some practices make the results available to patients — sometimes for a fee.

Washington Radiology didn’t respond to interview requests, but in a video on its website describing the practice’s “Mammo+Heart” AI screening, Islamiat Ego-Osuala, a breast imaging radiologist there, said, “If the past few decades has taught us anything about the field of radiology, it is that the sky’s the limit. The possibilities are endless.”

Some imaging experts question that rosy assessment as it relates to screening for breast arterial calcification to gauge heart disease risk.

“What we’re seeing on the mammogram is calcification in the breast artery, but that’s not the same as the calcification in the coronary artery,” said Greg Sorensen, chief science officer at RadNet, which has nearly 400 imaging centers in eight states. RadNet doesn’t offer breast arterial calcification screening and has no plans to. “It doesn’t feel like it’s delivering value today,” Sorensen said.

(RadNet does offer patients an AI analysis of their mammograms to improve breast cancer detection. KFF Health News reported on that earlier this year.)

Coronary artery calcification is recognized as a strong marker of heart disease risk. But while studies have shown an association between breast arterial calcification and the risk of cardiovascular disease, questions remain.

For one thing, even women who don’t have breast arterial calcification might still be at risk of heart disease, heart attack, or stroke. In a study of postmenopausal women, 26% had breast arterial calcification, and over a 6½-year study period it was associated with a 23% increased risk of heart disease of any kind and a 51% increase in risk of heart attack or stroke. However, most cardiovascular events happened to women who did not have breast arterial calcification.

“I wouldn’t feel comfortable telling people they have a higher or lower risk of heart disease based on their breast arterial calcification,” said Sadiya Khan, a preventive cardiologist at Northwestern Medicine in Chicago who co-authored a medical journal editorial commenting on the study. “I think this is an exciting area, but we need to move cautiously.”

It’s understandable that women’s health clinicians would be eager to embrace the idea of using the annual breast cancer screening that millions of women get every year to screen for heart disease risk as well.

Heart disease is the No. 1 killer in the United States. It was responsible for more than 300,000 — or roughly 1 in 5 — women’s deaths in 2021.

Many women don’t recognize their heart disease risk or the many factors that increase it, such as high blood pressure, diabetes, high cholesterol, smoking, drinking too much alcohol, and being overweight.

Online calculators can help people assess their risk of cardiovascular disease. For those whose 10-year risk is 7.5% or higher, clinicians may recommend lifestyle changes and/or prescribe a statin to lower blood cholesterol. Laura Heacock, a radiologist who specializes in breast imaging at NYU Langone Health in New York City, pointed out that patients already can get much of the information resulting from breast arterial calcification scoring from their physicians and use of those risk calculators. The key is that breast arterial calcification screening provides another chance to talk about heart disease risk.

One study found that 57% of women who were informed that they had breast arterial calcification after a mammogram reported they had discussed their results with their primary care physician or a cardiologist.

Heacock said she’d like to see more studies showing that reporting breast arterial calcification leads to changes in patient care and fewer heart attacks and strokes.

Every woman who visits the Lynn Women’s Health and Wellness Institute in Boca Raton, Florida, for a mammogram is screened for breast arterial calcification. It’s been a standard service since 2020, said Heather Johnson, a preventive cardiologist at the center. If calcification is found, the woman is referred to a cardiologist or other health care practitioner at the center to discuss the findings and get more information about heart disease risk.

Johnson acknowledged that more studies are needed to understand the connection between calcification in breast arteries and heart disease. Still, she said, the screening “allows a communication pathway.”

Patients at the Boca Raton institute aren’t charged for the screening.

This article was produced by KFF Health News, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — the independent source for health policy research, polling, and journalism. 

Mothering Over Meds: Docs Say Common Treatment for Opioid-Exposed Babies Isn’t Necessary

On learning last year she was pregnant with her second child, Cailyn Morreale was overcome with fear and trepidation.

“I was so scared,” said Morreale, a resident of the small western North Carolina town of Mars Hill. In that moment, her joy about being pregnant was eclipsed by fear she would have to stop taking buprenorphine, a drug used to treat opioid withdrawal that had helped counter her addiction.

Morreale’s fear was compounded by the rigidity of the most common approach to treating babies born after being exposed in the womb to opioids or some medications used to treat opioid addiction.

For decades throughout the opioid crisis, most doctors have relied on medication-heavy regimens to treat babies who are born experiencing neonatal opioid withdrawal syndrome. Those protocols often meant separating newborns from their mothers, placing them in neonatal intensive care units, and giving them medications to treat their withdrawal.

But research has since indicated that in many, if not most, cases, those extreme measures are unnecessary. A newer, simpler approach that prioritizes keeping babies with their families called Eat, Sleep, Console is being increasingly embraced.

In recent years, doctors and researchers have found that keeping babies with their mothers and ensuring they’re comfortable often works better and gets them out of the hospital faster.

Despite her worst fears, Morreale was never separated from her son. She was able to begin breastfeeding immediately. In fact, she was told, the trace of buprenorphine in her breast milk would help her son withdraw from it.

Her experience was different because she had found her way to Project CARA, an Asheville, North Carolina-based program, administered through the Mountain Area Health Education Center, that supports pregnant people and parents with substance use disorders. Morreale’s care team assured her she did not need to discontinue buprenorphine and that her baby would be assessed and monitored using the Eat, Sleep, Console approach. The protocol deems babies OK to be sent home so long as they’re eating, sleeping, and consolable when upset.

“By the grace of God, he was awesome,” Morreale said of her son.

A portrait of David Baltierra, a man with a short gray beard and glasses.
David Baltierra, a family physician and former director of West Virginia University’s Rural Family Medicine Residency Program, and his colleagues have been training residents to use an Eat, Sleep, Console approach for a decade.(Taylor Sisk for KFF Health News)

David Baltierra, former director of West Virginia University’s Rural Family Medicine Residency Program, chair of WVU’s Department of Family Medicine – Eastern Division, and a family physician, suggests this protocol could simply be called “parenting.”

The method is increasingly being used instead of the long-embraced approach to treating opioid-affected newborns called the Finnegan Neonatal Abstinence Scoring System. That tool includes a list of 21 questions (is the baby crying excessively, sweating, experiencing tremors, sneezing, etc.), the answers to which determine whether the newborn should get medication to counteract withdrawal symptoms, which would then require an extended stay in a neonatal ICU.

Baltierra, though, has issues with the Finnegan method. For example, it often results in a soundly sleeping baby being awakened to be scored. That didn’t make sense to Baltierra. If the baby is sleeping, she’s likely doing fine.

Instead, health professionals should look for the telltale signs of a baby experiencing opioid withdrawal syndrome, he said. “Their body is in tension, they have a high pitch, they don’t calm down.”

Baltierra and his colleagues have been training residents to use an Eat, Sleep, Console approach for a decade, progressively more so in the past six years. The results are persuading more health professionals to adopt the method.

A 2023 study found babies treated this way were discharged from the hospital in nearly half the time and less likely to receive medication than those receiving Finnegan-based care.

Matthew Grossman, an associate professor of pediatrics at the Yale School of Medicine, refers to the introduction of the model of treatment he has helped pioneer as “the least innovative” undertaking imaginable.

Research shows that optimal care for pregnant women who’ve experienced opioid use disorder includes treatment with buprenorphine or methadone, which carries the risk their newborn will have withdrawal symptoms. Grossman and colleagues found a non-pharmacological-first approach works best.

He said the Finnegan tool is useful but often too rigid. Under its scoring, one sneeze too many could send a baby to the NICU for weeks.

Grossman said he observed that some babies receiving medications did well for a few days but began to decline when their mothers were sent home without them. Those observations made him ask, “Did the kid need more medicine, or more mom?”

Research by Leila Elder and Madison Humerick, who each did their residency in WVU’s rural program, found that median stays for newborns in withdrawal dropped from 13 days in 2016 to three in 2020.

Elder said babies born at the 25-bed rural hospital where they performed deliveries received medications to treat their withdrawal symptoms only when unrelated issues sent them to other hospitals for NICU care.

A portrait of Leila Elder, a woman with short brown hair and glasses. She has a stethoscope hanging from her neck.
Family medicine physician Leila Elder co-produced research that found, at a hospital increasing its use of the Eat, Sleep, Console approach, median stays for newborns in withdrawal dropped from 13 days in 2016 to three in 2020.(Taylor Sisk for KFF Health News)

The simpler treatment also means more babies born in rural communities can receive care closer to home and has reduced the likelihood a mother will be released before her baby is cleared to go home.

Grossman suggested that rural hospitals are better suited to employ the Eat, Sleep, Console approach than big-city institutions, given the latter’s generally easier access to a NICU and propensity to choose that option.

Sarah Peiffer recalls the first time, as a medical student, she witnessed a nurse administering the Finnegan protocol, discussing it in clinical terms at a new mother’s bedside.

“And I remember being kind of horrified,” she said. The process was clearly distressing to both mother and child. “I felt like there was almost a punitive feeling to it, like we were telling this mom, ‘Look what you did to your baby.’”

Peiffer is now a Project CARA practitioner and family health physician at Blue Ridge Health in western North Carolina and a vocal proponent of ESC and its approach to partnering with families. “You look at all the nonpharmacologic stuff you’re supposed to be doing — like keeping the lights low in the room, keeping the baby swaddled, doing as much skin-to-skin with mom as possible — and you really treat mom as medicine.”

Research suggests immediate postbirth skin‐to‐skin contact offers “vital advantages” to short‐ and long‐term health and bonding.

That contact, Elder said, “releases endorphins for mom,” which helps lower the risk of postpartum depression.

Grossman said developing the Eat, Sleep, Console protocol was simply a matter of pausing to reassess.

The original intent of the Finnegan tool wasn’t to render the process so rigid. But “everybody is excited to have a tool, and then this approach calcified around it,” he said.

Grossman said the objective of the simpler approach was to place the family at the core of care, and shorter hospital stays for babies was simply a fortuitous outcome. The shift in approach fits into a wider move toward judgment-free, family-centered care for those who’ve experienced addiction and for their children.

Now, he said, after five days, mothers often say “‘Can we go home? I think I got this,’” and they’re treated “with the same respect as any other mom.”

Peiffer said she has witnessed this mother-centric care counter “that sense of shame that people feel instead of families feeling empowered to care for their infant.” It represents “such a major shift in how we think about neonatal withdrawal both medically and culturally.”

This article was produced by KFF Health News, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — the independent source for health policy research, polling, and journalism. 

A 37% Drop in Overdose Deaths From Drugs Mixed with Opioids – Fentanyl Included

Original post: Newswise - Substance Abuse A 37% Drop in Overdose Deaths From Drugs Mixed with Opioids - Fentanyl Included

COLUMBUS, Ohio – Expanded treatment options, increased naloxone distribution and targeted education campaigns likely led to a 37% reduction in overdose deaths from opioids combined with stimulant drugs other than cocaine, according to the results of a large federally funded study. 

The finding came from a planned study of secondary outcomes of the HEALing (Helping to End Addiction Long-Term) Communities Study (HCS), which tested an intervention encompassing data-driven adoption of evidence-based practices for reducing overdose deaths in Kentucky, Massachusetts, New York and Ohio. 

Death rates from specific combinations of opioids with stimulants other than cocaine, most commonly fentanyl mixed with methamphetamine, were 8.9 per 100,000 adults in intervention communities compared to 14.1 per 100,000 adults in comparison communities that did not receive the intervention – a statistically significant difference. 

The findings were published today (Oct. 21, 2024) in JAMA Network Open

With the prescription medications that started the opioid crisis harder to obtain by the time the trial began, fentanyl was rapidly entering the illicit drug market in combination with methamphetamine, cocaine, counterfeit pills and other stimulants, said Bridget Freisthler, lead author of the new study and a professor at The Ohio State University. 

“Now we have a whole new group of people developing addiction to opioids,” said Freisthler, Ohio’s principal investigator for the HEALing Communities Study. “It was nice to see that we were able to achieve reductions in overdose deaths involving this combination of opioids, primarily fentanyl and psychostimulants, not including cocaine, because that’s the most recent wave in the epidemic that we’re seeing.” 

Analysis of other drug combinations showed that intervention communities had lower rates of overdose deaths from an opioid mixed with cocaine (6%) and an opioid mixed with benzodiazepine (1%), but that these differences did not reach statistical significance. 

The National Institutes of Health (NIH) launched the HEALing Communities Study in 2019. Participating community coalitions implemented 615 strategies to address opioid-related overdose deaths across health care, justice and behavioral health settings. Based on data indicating which interventions were best suited to areas they served, agencies selected from three “menus” of evidence-based practices focused on overdose education and naloxone distribution, increasing exposure to medication for opioid use disorder, and safer opioid prescribing.  

Researchers reported in June on the main outcome of HCS – that the intervention did not result in a statistically significant reduction in opioid overdose death rates during the evaluation period. In this study, the authors found that intervention communities had an 8% lower rate of all drug overdoses compared to control communities, which was estimated to represent 525 fewer drug overdose deaths. 

In the new paper, researchers reported that more than 40% of overdose deaths in the study involved the combination of at least one opioid and a stimulant. 

The evidence of higher prevalence of fentanyl in the illicit drug market led coalition agencies to adjust communication efforts accordingly, said Freisthler, also the Cooper-Herron Professor in Mental Health at the University of Tennessee, Knoxville

“We were already shifting to where psychostimulants had fentanyl in them and messages weren’t reaching the right folks because people who use psychostimulants think of themselves as using meth or cocaine, not opioids,” she said. “So we had to make it clear that fentanyl could be in every drug and that nobody was really immune from the possibility of an overdose. Communities emphasized that this is a multiple-drug issue, not just a fentanyl issue or an opioid issue. 

“In many ways, the fact we’re looking at this particular outcome is because communities were so invested in it and so concerned, and wanted it to be a focus of the study.”

The potential for naloxone to prevent overdose deaths in people who use multiple drugs was also incorporated into communication campaigns implemented by all intervention communities, which may have helped prevent deaths, researchers said. 

Participating agencies were very good at advocating for themselves, Freisthler said, and the front-end work ideally will leave communities even better prepared to address overdoses going forward. 

“The HCS was beneficial to Brown County in numerous ways,” said Deanna Vietze, executive director of the Brown County Board of Mental Health and Addiction Services in southwest Ohio. “It affirmed the work already underway, allowed for expansion of best practices, helped engage new partners, strengthened existing partnerships, and allowed innovative purchases that forged outreach opportunities that will continue to positively impact Brown County citizens for years to come.” 

Ohio study leaders are intent on making sure lessons and success stories from the study are widely available through a website providing a range of materials, and are meeting with groups interested in implementing the evidence-based practices in their own communities.

“The drug overdose crisis is pervasive in our communities, and we’ve got multigenerational and intergenerational trauma affecting families. That’s not going to change overnight,” Freisthler said. “That means we need to continue to improve understanding of this crisis, and reduce overdose deaths so we don’t have another generation experiencing the same sort of trauma.” 

The HEALing Communities Study was supported and carried out in partnership between the National Institute on Drug Abuse and the Substance Abuse and Mental Health Services Administration through the NIH HEAL Initiative.  

$65.9 million NIH award funding Ohio State’s leadership of the Ohio portion of the study was housed in the university’s College of Medicine. Co-authors of the paper included study site principal investigators Sharon Walsh of the University of Kentucky, Nabila El-Bassel of Columbia University, T. John Winhusen of the University of Cincinnati, Jeffrey Samet of Boston Medical Center and Emmanuel Oga of RTI International.

Contact: Bridget Freisthler, [email protected]

Written by Emily Caldwell, [email protected]

Watch: ‘Silence in Sikeston & The Effects of Racial Violence’

KFF Health News Midwest correspondent Cara Anthony appeared in a two-part special of Nine PBS’ “Listen, St. Louis with Carol Daniel” to discuss her reporting for the “Silence in Sikeston” project.

The first conversation, which aired Oct. 9, explores the connections between a 1942 lynching and a 2020 police shooting in a rural Missouri community — and what those killings say about the nation’s silencing of racial trauma. The second episode, which premiered Oct. 16, explores the health effects of such trauma with mental health counselor Lekesha Davis.

These conversations stem from the “Silence in Sikeston” multimedia project by KFF Health News, Retro Report, and WORLD, which includes a documentary film, educational videos, digital articles, and a limited-series podcast.

[embedded content]
[embedded content]

Explore more of the “Silence in Sikeston”project:

LISTEN: The limited-series podcast is available on PRX, Apple Podcasts, Spotify, iHeart, or wherever you get your podcasts.

WATCH: The documentary film “Silence in Sikeston,” a co-production of KFF Health News and Retro Report, is available to stream on WORLD’s YouTube channel, WORLDchannel.org, and the PBS app.

READ: KFF Health News Midwest correspondent Cara Anthony wrote an essay about what her reporting for this project helped her learn about her own family’s hidden past.

Beneficiarios de Medicare gastarán menos en medicamentos en 2025

Cuando Pam McClure se enteró que el próximo año ahorraría casi $4,000 en sus medicamentos recetados dijo: “parece demasiado bueno para ser verdad”.

Para finales de 2024, habrá gastado casi $6,000 en estos fármacos, incluido uno para controlar su diabetes.

McClure, de 70 años, es una de las aproximadamente 3.2 millones de personas con un plan de medicamentos recetados de Medicare cuyos costos de bolsillo se limitarán a $2,000 en 2025 gracias a la Ley de Reducción de la Inflación (IRA, por sus siglas en inglés) de 2022 promulgada por la administración Biden, según un estudio de Avalere/AARP.

La IRA, una ley de atención médica y clima que el presidente Joe Biden y la vicepresidenta Kamala Harris promueven en la campaña como uno de los mayores logros de su administración, rediseñó radicalmente el beneficio de medicamentos de Medicare, conocido como Parte D, que sirve a unas 53 millones de personas de 65 años o más, o que viven con ciertas discapacidades.

Gracias a este nuevo límite en el gasto de bolsillo y otros cambios importantes, pero menos conocidos, la administración estima que alrededor de 18.7 millones de personas ahorrarán aproximadamente $7.4 mil millones solo el próximo año.

El período de inscripción anual para que los beneficiarios de Medicare renueven o cambien su cobertura de medicamentos, o elijan un plan Medicare Advantage, comenzó el 15 de octubre y se extiende hasta el 7 de diciembre. Medicare Advantage es la alternativa comercial al Medicare tradicional administrado por el gobierno y cubre atención médica y, a menudo, medicamentos recetados.

Los planes de medicamentos independientes de Medicare, que cubren medicamentos que normalmente se toman en casa, también son administrados por compañías de seguros privadas.

“Siempre alentamos a los beneficiarios a que realmente revisen los planes y elijan la mejor opción para ellos”, dijo Chiquita Brooks-LaSure, quien dirige los Centros de Servicios de Medicare y Medicaid (CMS, por sus siglas en inglés), a KFF Health News. “Y este año, en particular, es importante hacerlo porque el beneficio ha cambiado mucho”.

Las mejoras a la cobertura de medicamentos de Medicare requeridas por la IRA son los cambios más importantes desde que el Congreso agregó el beneficio en 2003, pero la mayoría de los votantes no los conocen, según encuestas de KFF, una organización sin fines de lucro de información sobre salud que incluye a KFF Health News. Y algunos beneficiarios pueden sorprenderse por un inconveniente: algunos planes aumentarán sus primas.

El 27 de septiembre, los CMS dijeron que, a nivel nacional, la prima promedio de los planes de medicamentos de Medicare disminuyó alrededor de $1.63 al mes —aproximadamente un 4%— respecto al año pasado.

“Las personas inscritas en un plan de la Parte D de Medicare seguirán viendo primas estables y tendrán amplias opciones de planes asequibles”, dijeron los CMS en un comunicado.

Sin embargo, un análisis de KFF encontró que “muchas aseguradoras están aumentando las primas” y que grandes aseguradoras como UnitedHealthcare y Aetna también redujeron la cantidad de planes que ofrecen.

Las propuestas iniciales de primas de muchas aseguradoras de la Parte D para 2025 fueron aún más altas. Para amortiguar el impacto del precio, la administración Biden creó lo que llama un programa de demostración para pagar a las aseguradoras $15 adicionales al mes por beneficiario si aceptaban limitar los aumentos de primas a no más de $35.

“En ausencia de esta demostración, los aumentos de primas ciertamente habrían sido mayores”, escribió Juliette Cubanski, subdirectora del Programa de Políticas de Medicare en KFF, en su análisis del 3 de octubre.

Casi todas las aseguradoras de la Parte D aceptaron el acuerdo. Los republicanos lo han criticado, cuestionando la autoridad de los CMS para hacer los pagos adicionales y llamándolos una maniobra política en un año electoral.

Sea cual sea la razón, las primas están subiendo dramáticamente para algunos planes.

En el estado de Nueva York, por ejemplo, la prima del popular plan Value Script de Wellcare pasó de $3.70 mensuales a $38.70 el próximo año, un aumento de $35, más de diez veces que el costo actual.

An excerpted portion of a booklet showing a premium increase.
Una página de un “aviso de cambios” que Wellcare envió a los clientes de su plan de medicamentos de Medicare Value Script en Nueva York. El folleto de 28 páginas no explica por qué se aumentó la prima ni cómo se calculó. “Esperamos mantenerlo como miembro el año que viene”, dice el folleto, antes de explicar cómo cambiar de plan.(Susan Jaffe for KFF Health News)

Cubanski identificó ocho planes en California que aumentaron sus primas exactamente $35 al mes. KFF Health News encontró que las primas aumentaron en al menos el 70% de los planes de medicamentos ofrecidos en California, Texas y Nueva York, y en alrededor de la mitad de los planes en Florida y Pennsylvania, los cinco estados con más beneficiarios de Medicare.

Voceros de Wellcare y de su empresa matriz, Centene Corp., no respondieron a las solicitudes de comentarios. En una declaración este mes, la vicepresidenta senior de servicios clínicos y especializados de Centene, Sarah Baiocchi, dijo que Wellcare ofrecería el plan Value Script sin prima en 43 estados.

Además del límite de $2,000 en el gasto de medicamentos, la IRA limita los copagos de Medicare para la mayoría de los productos de insulina a no más de $35 al mes y permite que Medicare negocie directamente los precios de algunos de los medicamentos más caros directamente con las farmacéuticas.

También eliminará una de las características más frustrantes del beneficio de medicamentos, una brecha conocida como el “agujero de dona (doughnut hole)” que suspende la cobertura justo cuando las personas enfrentan crecientes costos de medicamentos, obligándolas a pagar el precio completo de las drogas de su plan de su bolsillo hasta que alcancen un umbral de gasto que cambia de un año a otro.

La ley también amplía la elegibilidad para los subsidios de “ayuda adicional” para aproximadamente 17 millones de personas de bajos ingresos en los planes de medicamentos de Medicare y aumenta el monto del subsidio. Las farmacéuticas deberán contribuir para ayudar a pagarlo.

A partir del 1 de enero, el beneficio de medicamentos rediseñado funcionará más como otras pólizas de seguro privado. La cobertura comienza después que los pacientes paguen un deducible, que no será mayor de $590 el próximo año. Algunos planes ofrecen un deducible menor o ninguno, o excluyen ciertos medicamentos, generalmente genéricos baratos, del deducible.

Después que los beneficiarios gasten $2,000 en deducibles y copagos, el resto de sus medicamentos de la Parte D serán gratuitos.

Eso se debe a que la IRA aumenta la parte de la factura asumida por las aseguradoras y las compañías farmacéuticas. La ley también intenta frenar futuros aumentos de precios de medicamentos al limitar los aumentos a la tasa de inflación al consumidor, que fue del 3.4% en 2023. Si los precios suben más rápido que la inflación, las farmacéuticas deben pagar a Medicare la diferencia.

“Antes del rediseño, la Parte D incentivaba los aumentos de precios de los medicamentos”, dijo Gina Upchurch, farmacéutica y directora ejecutiva de Senior PharmAssist, una organización sin fines de lucro en Durham, Carolina del Norte, que asesora a beneficiarios de Medicare. “La forma en que está diseñada ahora coloca más obligaciones financieras en los planes y los fabricantes, presionándolos para que ayuden a controlar los precios”.

Otra disposición de la ley permite a los beneficiarios pagar los medicamentos en un plan de pago a plazos, en lugar de tener que pagar una factura abultada en un corto período de tiempo.

Las aseguradoras deben hacer los cálculos y enviar una factura mensual a los titulares de pólizas, que se ajustará si se agregan o eliminan medicamentos.

Junto con los grandes cambios introducidos por la IRA, los beneficiarios de Medicare deben prepararse para las sorpresas inevitables que surgen cuando las aseguradoras revisan sus planes para un nuevo año. Además de aumentar las primas, las aseguradoras pueden eliminar medicamentos cubiertos y eliminar farmacias, médicos u otros servicios de las redes de proveedores que los beneficiarios deben usar.

Perder la oportunidad de cambiar de plan significa que la cobertura se renovará automáticamente, incluso si cuesta más o ya no cubre los medicamentos que el afiliado necesito o sus farmacias preferidas.

La mayoría de los beneficiarios no pueden realizar ningún cambio en sus planes, o pasar a otros por fuera del período de inscripción annual, a menos que los CMS les otorgue un “período de inscripción especial”.

Sin embargo, muchos no se toman el tiempo para comparar docenas de planes que pueden cubrir diferentes medicamentos a diferentes precios en diferentes farmacias, incluso cuando el esfuerzo podría ahorrarles dinero.

En 2021, solo el 18% de los inscritos en planes de medicamentos de Medicare Advantage y el 31% de los miembros de planes de medicamentos independientes compararon los beneficios y costos de su plan con los de los competidores, según encontraron investigadores de KFF.

Para obtener ayuda gratuita e imparcial para elegir un plan de medicamentos, los beneficiarios pueden comunicarse con el Programa de Asistencia Estatal de Seguros de Salud (SHIP) de su estado en shiphelp.org o en la línea de ayuda 1-877-839-2675.